Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated from v3.5.2 to v3.5.3, indicating a new build of the page. The listed change does not alter study content, eligibility criteria, or results.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to study details or page behavior.SummaryDifference0.1%

- Check59 days agoChange DetectedVersion updated from v3.4.2 to v3.4.3. No user-facing content or study details appear to be changed.SummaryDifference0.1%

- Check88 days agoChange DetectedRevision: v3.4.2 is now shown; the prior funding-related notice and the v3.4.1 revision have been removed, with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check95 days agoChange DetectedIntroduced a government funding update notice and updated the site revision to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.